Alvotech Annual General Meeting to be held June 25, 2025
The Annual General Meeting of Alvotech will be held on Wednesday June 25, 2025, at 09.00 a.m. CEST at the premises of Arendt & Medernach at 41A, Avenue John F. Kennedy L-1855 Luxembourg, Grand Duchy of Luxembourg.
Reference is made to the attached document with regard to the final agenda.
Advertisement
Meeting materials and all further information about the Annual General Meeting is available on the Alvotech website: https://investors.alvotech.com/corporate-governance/annual-general-meeting-2025
CONTACTS
Alvotech Investor Relations
Benedikt Stefansson, VP
[email protected]
Attachment
Convening notice – AGM 2025
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
Result of AGM
LONDON--(BUSINESS WIRE)-- 26 June 2025 Next 15 Group plc ('Next 15' or the 'Company') Results of Annual General Meeting Next 15 Group plc announces that at its Annual General Meeting held at 9:30am on 26 June 2025 at 60 Great Portland Street, London, W1W 6RT, all resolutions set out in the Notice of Annual General Meeting dated 6 May 2025, other than resolution 8 which was withdrawn, were duly passed by shareholders. Resolutions 1 to 13 were Ordinary Resolutions and Resolutions 14 to 17 were Special Resolutions. A summary of the resolutions passed and details of the proxy votes received are detailed below: Resolutions Votes For1 Votes Against Total Votes Cast Votes Witheld3 No. of Shares % of Shares voted No. of Shares % of Shares voted No. of Shares % of ISC voted2 1 To receive and adopt the Annual Report & Accounts for the year ended 31 January 2025 79,016,751 99.99% 371 0.01% 79,017,122 78.29% 298,772 2 To receive and approve the Directors' Remuneration Report for the year ended 31 January 2025 71,326,326 89.93% 7,986,123 10.07% 79,312,449 78.59% 3,445 3 To declare a final dividend of 10.6p per ordinary share 79,313,728 99.99% 371 0.01% 79,314,099 78.59% 1,795 4 To elect Mark Astaire as a Director 79,303,363 99.99% 6,088 0.01% 79,309,451 78.58% 6,443 5 To elect Mickey Kalifa as a Director 79,283,399 99.97% 27,752 0.03% 79,311,151 78.58% 4,743 6 To elect Samantha Wren as a Director 79,305,844 99.99% 4,088 0.01% 79,309,932 78.58% 5,962 7 To re-elect Penny Ladkin-Brand as a Director 76,572,297 98.52% 1,152,791 1.48% 77,725,088 77.01% 1,590,806 9 To re-elect Jonathan Peachey as a Director 79,282,994 99.97% 26,457 0.03% 79,309,451 78.58% 6,443 10 To re-elect Paul Butler as a Director 78,982,960 99.59% 326,491 0.41% 79,309,451 78.58% 6,443 11 To re-appoint Deloitte LLP as Auditor to the Company 79,171,833 99.82% 139,401 0.18% 79,311,234 78.58% 4,660 12 To authorise the Audit and Risk Committee (for and on behalf of the Board of Directors) to determine the Auditors' remuneration 79,173,104 99.82% 138,944 0.18% 79,312,048 78.59% 3,846 13 To authorise the Board to allot shares 70,538,545 88.95% 8,765,534 11.05% 79,304,079 78.58% 11,815 14 To authorise the disapplication of pre-emption rights 71,704,464 90.42% 7,599,765 9.58% 79,304,229 78.58% 11,665 15 To authorise the disapplication of pre-emption rights for the purposes of acquisitions or specified capital investment 70,085,275 88.38% 9,218,954 11.62% 79,304,229 78.58% 11,665 16 To authorise the Company to purchase its own shares 66,638,948 99.99% 3,033 0.01% 66,641,981 66.03% 12,673,913 17 That, subject to court approval, the amount standing to the credit of the Company's share premium account be cancelled 79,308,291 99.99% 5,387 0.01% 79,313,678 78.59% 2,216 Expand 1 Includes discretionary votes. 2 As at 24 June 2025, being the AGM voting record date, the Company's issued share capital ('ISC') consisted of 100,924,813 ordinary shares of 2.5p each ('Ordinary Shares'). No Ordinary Shares are held in treasury. Shareholders are entitled to one vote per share. 3 A "Vote Withheld" is not a vote in law and is not included in the calculation of votes "For" or "Against" a resolution. Expand Enquiries Next 15 Group plc Mark Sanford, General Counsel & Company Secretary +44 (0) 7590 928794 Deutsche Numis (Nomad & Joint Broker) +44 (0)20 7260 1000 Mark Lander Hugo Rubinstein Berenberg (Joint Broker) +44 (0)20 3207 7800 Ben Wright Mark Whitmore MHP Simon Evans Eleni Menikou Veronica Farah +44 (0)7812 590 682 Next15@ Expand
Yahoo
4 hours ago
- Yahoo
Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility
REYKJAVIK, Iceland, June 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the 'Company'), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its lenders under the Company's existing senior secured term loan facility, including GoldenTree Asset Management (collectively, the 'Lenders'), have agreed to reduce the rate of interest on its existing senior secured term loan facility (the 'Facility'). The agreement will lower Alvotech's interest payments in the first 12 months by an estimated US$8.2 million. This is an outcome of Alvotech's sustained operational improvements and strengthened financial performance over the past year. 'Since last year, we have shown significant revenue growth, operating profits and positive adjusted EBITDA, and we expect to be able to fund future growth based on milestone and product revenue. Being able to reduce our cost of capital demonstrates great confidence, by a group of experienced healthcare investors, in Alvotech's leadership, our pipeline progress and prospects for near-term product launches.' said Joel Morales, Chief Financial Officer of Alvotech. The Facility was funded in July 2024 and matures in July 2029. It originally consisted of two tranches: a $900 million first-out term loan tranche (the 'first tranche'), with an interest rate of SOFR plus 6.5% per annum, and a $65 million second-out term loan tranche (the 'second tranche'), with an interest rate of SOFR plus 10.5% per annum. In conjunction with this transaction, certain of the Lenders have agreed to increase the first tranche to include the second tranche, creating one single tranche going forward, further simplifying Alvotech's capital structure. The interest rate for this Facility will be SOFR plus 6.0% per annum, and all interest will be payable in cash. Following this transaction, the balance of the Facility is approximately $1,081 million and the Company's cash balance was approximately $152 million, as of June 25, 2025. About AlvotechAlvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit None of the information on the Alvotech website shall be deemed part of this press release. About GoldenTreeGoldenTree is an employee-owned, global asset management firm that specializes in opportunities across the credit universe in sectors such as high yield bonds, leveraged loans, private credit, distressed debt, structured products, emerging markets, real estate, private equity and credit-themed equities. GoldenTree was founded in 2000 by Steven A. Tananbaum and is one of the largest independent global credit asset managers. GoldenTree manages $58 billion for institutional investors, including leading public and corporate pensions, endowments, foundations, insurance companies and sovereign wealth funds. GoldenTree has over 310 employees, with offices in New York, West Palm Beach, Charlotte, Newport Beach, Dallas, London, Dublin, Munich, Singapore, Sydney, Tokyo and Dubai. For more information, please visit Forward Looking StatementsCertain statements in this communication may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial operating performance of Alvotech and may include, for example, Alvotech's expectations regarding its ability to comply with the covenants of the Facility and to exercise its rights under the Facility, estimated cost savings resulting of the agreement, potential future financings or strategic transactions, Alvotech's competitive advantages, business prospects and opportunities including product launches, pipeline product development, revenue and diversification, future plans and intentions, results, level of activities, financial and operations performance, goals or achievements or other future events, and market launches. In some cases, you can identify forward-looking statements by terminology such as 'may', 'should', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential', 'aim' or 'continue', or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the ability to raise substantial additional funding, which may not be available on acceptable terms or at all; (2) the ability to maintain stock exchange listing standards; (3) changes in applicable laws or regulations; (4) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (5) Alvotech's estimates of revenue, expenses and profitability; (6) Alvotech's ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (7) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (8) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (9) the ability of Alvotech's partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (10) Alvotech's ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (11) the success of Alvotech's current and future collaborations, joint ventures, partnerships or licensing arrangements; (12) Alvotech's ability, and that of its commercial partners, to execute their commercialization strategy for approved products; (13) Alvotech's ability to manufacture sufficient commercial supply of its approved products; (14) the outcome of ongoing and future litigation regarding Alvotech's products and product candidates; (15) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, conflicts in Ukraine, the Middle East and other global geopolitical tension, on the Company's business, financial position, strategy and anticipated milestones; (16) Alvotech's ability to comply with the covenants of the Facility and (17) other risks and uncertainties set forth in the sections entitled 'Risk Factors' and 'Cautionary Note Regarding Forward-Looking Statements' in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication. ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONSBenedikt Stefansson, FOR MORE INFORMATIONPlease visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
15 hours ago
- Business Upturn
Main Results of 2025 Annual and Extraordinary General Meeting
The 2025 Annual and Extraordinary General Meeting (the '2025 AGM') of Alvotech (the 'Company') was held on June 25, 2025, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg. All of the draft resolutions on the 2025 AGM agenda were approved. Notarized meeting minutes and voting results will be published on the Company's special web portal for the 2025 Annual General Meeting at: Advertisement Alvotech Investor Relations Benedikt Stefansson [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
